PEACE-1: Phase III Trial of Abiraterone With or Without Local Radiotherapy + SoC in de novo Metastatic Castration-Sensitive Prostate Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
In patients with metastatic castration-sensitive prostate cancer, the addition of abiraterone to standard of care, ADT with or without docetaxel, prolonged median radiographic PFS by more than 2 years.
Format: Microsoft PowerPoint (.ppt)
File Size: 453 KB
Released: June 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in androgen deprivation therapy for prostate cancer

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: October 6, 2021 Expired: October 5, 2022

Health-related quality of life, pain, safety outcomes from VISION trial of 177Lu-PSMA-617 in men with mCRPC presented at the 2021 ESMO Congress, reported by Clinical Care Options (CCO)

Released: September 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue